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 Abstract 
 Background: Soluble urokinase plasminogen activator 
receptor (suPAR) is a biomarker increasingly used for the 
assessment of systemic inflammation. We aimed to evalu-
ate suPAR for the assessment of inflammatory activity in 
rheumatoid arthritis (RA) patients in remission. 
 Methods: In our cross-sectional study we measured 
plasma suPAR and C-reactive protein (CRP) levels as well 
as erythrocyte sedimentation rate (ESR) in 120 RA patients 
at various stages of disease activity and 29 healthy age-
matched controls. 
 Results: suPAR, CRP and ESR values were higher in RA 
patients compared to healthy individuals. When suPAR 
levels were analyzed according to DAS28 scores of RA 
patients, suPAR level in the subgroup with DAS28 ≤ 2.6 
was lower than in the subgroup with DAS28 > 2.6, but still 
higher than in controls [4.45 (3.33 – 5.56) ng/mL vs. 3.66 
(3.10 – 4.67) ng/mL vs. 2.80 (2.06 – 3.42) ng/mL, p < 0.0001, 
median (interquartile range)]. In contrast, CRP and ESR 
values were comparable in the subgroup with DAS28 ≤ 2.6 
and in healthy individuals. We further analyzed the corre-
lation between the number of tender and/or swollen joints 
and suPAR levels in RA patients in remission. suPAR val-
ues were significantly higher in patients with four tender 
and/or swollen joints than in patients with 2 – 3 or 0 – 1 ten-
der and/or swollen joints. 
 Conclusions: While CRP and ESR values indicate remis-
sion of the chronic inflammatory process in RA, suPAR 
values are still elevated compared to healthy individuals. 
suPAR might be particularly valuable in the recognition 
of inflammatory activity in patients who are in remission 
according to DAS28 scores but have symptoms of tender 
and/or swollen joints. 
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 Introduction 
 Soluble urokinase plasminogen activator receptor (suPAR) 
is a biomarker increasingly used for the monitoring of sys-
temic inflammation. suPAR is derived from the cleavage 
and release of the membrane-bound protein, urokinase-
type plasminogen activator receptor (uPAR), expressed 
by various immune cells, trophoblasts, endothelial cells, 
smooth muscle cells, and by certain tumor cells  [1, 2] . 
suPAR is detectable in low, but constant concentrations 
in plasma of healthy individuals  [3, 4] . However, activa-
tion of the immune system and the development of an 
inflammatory response lead to elevated plasma suPAR 
concentrations. The plasma level of suPAR is increased in 
infectious  [5, 6] , autoimmune  [7] , neoplastic  [8] and preg-
nancy-related  [9] diseases. Interestingly, in all of these 
conditions suPAR concentrations are directly proportional 
to a worse prognosis of the disease  [5, 6, 8, 10] . 
 Rheumatoid arthritis (RA) is also characterized by a 
chronic inflammatory response, resulting in the erosion 
of the cartilage and bone, and invasive growth of synovial 
pannus tissue. C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR) are widely used to assess the 
inflammatory status of RA patients, and are also used for 
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the calculation of Disease Activity Score (DAS28) in RA 
 [11] . RA is regarded as active above a DAS28 score of 2.6, 
however, patients in remission (DAS28 score  ≤ 2.6) might 
also be affected by inflammatory activity. Although it 
would have important prognostic and therapeutic conse-
quences in the follow-up of such patients, the sensitivity 
of routinely used inflammatory markers does not allow 
early detection of this condition. 
 Therefore, in our investigation, we aimed to evalu-
ate suPAR for the assessment of inflammatory activity in 
rheumatoid arthritis (RA) patients in remission. 
 Materials and methods 
 We enrolled 29 healthy individuals and 120 RA patients at various 
stages of disease duration and activity. Clinical parameters of study 
participants are summarized in Table  1 . Healthy individuals and RA 
patients were age and gender matched. RA patients were diagnosed 
and classifi ed according to the latest ACR/EULAR criteria  [12] . All 
RA patients were diagnosed at least 1 year before sampling. Patients 
with ongoing infection or cancer were excluded from the analysis. 
The median of RA duration was 27 months in the patient group, and 
the median of DAS28 activity score was 2.8, corresponding to low 
disease activity. DAS28 scores were calculated at the time of sam-
pling. All RA patients received a variety of disease modifying anti-
rheumatic drugs (DMARDs), containing at least one of the following 
components: methotrexate, lefl unomid, sulfasalazine, chloroquine. 
Thirty-four of 120 RA patients received anti-tumor necrosis factor 
(TNF) therapy, while 60 of 120 patients received glucocorticoid treat-
ment as well. Only patients with normal leukocyte count values were 
Characteristics Healthy 
individuals
n = 29
RA patients
n = 120
Age, years 55 (46 – 69) 61 (48 – 72)
Gender, male/female 10/18 46/74
RA duration, months  – 27 (16 – 52)
DAS28  – 2.8 (2.1 – 3.6)
Number of patients receiving 
anti-TNF therapy
 – 34 (28.3 % )
No. of patients receiving 
glucocorticoid therapy
 – 60 (50 % )
suPAR, ng/mL  2.80 
(2.06 –
 3.42)
4.24 a 
(3.19 – 5.40)
CRP, mg/L 2.70 
(BLD – 4.15)
4.00 a 
(BLD – 9.83)
ESR, mm/h 10 (7 – 14) 21 a (12 – 36.5)
 Table 1   Clinical characteristics of healthy individuals and RA 
patients. 
 Data are expressed as median (interquartile range).  a p < 0.05 vs. 
healthy individuals. 
included in the analysis. Healthy controls had a negative history of 
rheumatic symptoms and negative status upon detailed physical 
and laboratory examination. Written informed consent was obtained 
from all subjects, and our study was reviewed and approved by an 
independent Ethics Committee of the institution. Laboratory studies 
and interpretations were performed on coded samples lacking per-
sonal and diagnostic identifi ers. The study was adhered to the tenets 
of the most recent revision of the Declaration of Helsinki. 
 Plasma was isolated from EDTA anticoagulated fasting blood 
samples and stored at  – 80 ° C until measurement. Plasma suPAR con-
centrations were measured with the suPARnostic Flex ELISA assay 
(ViroGates A/S, Birker ø d, Denmark). CRP levels were measured using 
a Roche Hitachi 912 instrument with Roche Tina-quant CRP immu-
no-turbidimetric assay (Roche Diagnostics GmbH, Mannheim, Ger-
many). CRP values below the level of detection were regarded as  ‘ 1 ’ . 
For the determination of ESR, the Westergren method was performed 
according to ICSH specifi cations  [13] on undiluted EDTA anticoagu-
lated blood samples using glass pipettes (Greiner Bio-One, Kremsm-
uenster, Austria). During sedimentation, the pipettes were mounted 
vertically on appropriate supporting racks and kept at room tempera-
ture, which never exceeded 25 ° C. 
 Data are expressed as median (interquartile range). Comparisons 
between healthy individuals and RA patients were made with Mann-
Whitney tests. In case of comparisons between healthy controls and 
RA patient subgroups, the Kruskal-Wallis test was performed. To test 
the correlation between suPAR levels and other investigated param-
eters, Spearman tests were used. To exclude the potential independ-
ent eff ect of anti-TNF and glucocorticoid therapy on the assessed 
factors, multiple regression analysis was used. Area under the curve 
(AUC) values of receiver operating characteristics (ROC) curves were 
calculated using standard methods and data are presented as AUC 
ROC (95 % CI). p-Values  < 0.05 were considered signifi cant. Statistics 
were calculated using the R soft ware (R Development Core Team, R 
Foundation for Statistical Computing, Vienna, Austria). 
 Results 
 suPAR, CRP and ESR values were higher in RA patients 
compared to healthy individuals (Table 1). Correlation 
analyses revealed a correlation between suPAR values 
and DAS28 scores in RA patients (p = 0.02, r = 0.26, Figure 
 1 A), suPAR values and ESR values in RA patients (p = 0.05, 
r = 0.30, Figure 1B) and suPAR values and CRP values in 
healthy individuals (p = 0.02, r = 0.32, Figure 1C). 
 When suPAR levels were analyzed according to different 
subgroups of RA patients (according to DAS28 scores, anti-
TNF and glucocorticoid therapy, CRP and ESR values), the 
levels were higher in each subgroup compared to healthy 
controls. When suPAR levels were compared between the 
corresponding subgroups, the only difference detected was 
between the subgroup with a DAS28 score  ≤ 2.6 and the sub-
group with a DAS28 score  > 2.6 (Table  2 ). 
 CRP and ESR values were also analyzed according 
to subgroups of RA patients according to DAS28 scores 
(Table  3 ). Irrespectively of anti-TNF and glucocorticoid 
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 Figure 1   Correlation between suPAR plasma levels and other investigated parameters in different study groups. 
 (A) suPAR levels were correlated with DAS28 in all RA patients. (B) suPAR levels were correlated with ESR in all RA patients. (C) suPAR levels 
were correlated with CRP levels in healthy individuals. (D) suPAR levels were correlated with the number of tender and/or swollen joints in 
RA patients in remission. 
Study group suPAR, ng/mL
Healthy individuals 2.80 (2.06 – 3.42)
RA patients according to DAS28 score
   ≤ 2.6 (41.6 % ) 3.66 a (3.10 – 4.67)
   > 2.6 (58.4 % ) 4.45 a,b (3.33 – 5.56)
RA patients according to anti-TNF therapy
   Yes (28.3 % ) 4.19 a (3.15 – 6.15)
   No (71.7 % ) 4.24 a (3.18 – 4.95)
RA patients according to glucocorticoid therapy
   Yes (50 % ) 4.27 a (3.14 – 4.98)
   No (50 % ) 4.18 a (3.18 – 6.37)
RA patients according to CRP values
   ≤ 5 (47.5 % ) 4.19 a (3.12 – 4.94)
   > 5 (52.5 % ) 4.27 a (3.19 – 6.27)
RA patients according to ESR values
   ≤ 20 (46.6 % ) 4.04 a (3.15 – 4.86)
   > 20 (53.4 % ) 4.44 a (3.24 – 5.84)
 Table 2   suPAR levels in different subgroups of RA patients. 
 Data are expressed as median (interquartile range).  a p < 0.05 vs. 
healthy individuals,  b p < 0.05 vs. RA patients according to DAS28 
score  ≤ 2.6. 
therapy, CRP and ESR values were higher in the subgroup 
with a DAS28 score  > 2.6 than in RA patients in remission 
(DAS28 score  ≤ 2.6) or in healthy individuals. However, no 
difference was detected between patients in remission 
and healthy individuals. 
 We further analyzed the correlation between the 
number of tender and/or swollen joints and suPAR levels 
in RA patients in remission. A strong correlation was 
detected (p < 0.001, r = 0.8, Figure 1D). suPAR values were 
significantly higher in patients with four tender and/or 
swollen joints than in patients with 2 – 3 or 0 – 1 tender and/
or swollen joints. However, no difference was detected 
between groups of patients in remission according to the 
number of tender and/or swollen joints with regard to CRP 
and ESR values (Table  4 , Figure  2 ). 
 ROC analysis of suPAR values in RA patients in 
remission yielded an AUC of 0.996 (95 % CI 0.984 – 1.007, 
p = 0.0001, Figure  3 ). The cut-off value of suPAR to discrim-
inate between patients with four tender and/or swollen 
joints and those with 0 – 3 tender and/or swollen joints was 
4.785 ng/mL [sensiti vity % (95 % CI) 100.0 (71.51 – 100.0), 
specificity % (95 % CI) 95.24 (83.84 – 99.42)]. 
 Discussion 
 The severity of RA is evaluated based on laboratory 
markers and clinical symptoms. Prompt classification 
of patients according to disease activity has significant 
therapeutic consequences. Therefore, it is of importance 
to find reliable markers that enable a more objective 
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Study group suPAR, ng/mL CRP, mg/L ESR, mm/h
Healthy individuals 2.80 (2.06 – 3.42) 2.70 (BLD – 4.15) 10 (7 – 14)
RA patients according to DAS28 score
   ≤ 2.6 (41.6 % ) 3.66 a (3.10 – 4.67) 2.25 (BLD – 5.28) 13 (9 – 18)
   > 2.6 (58.4 % ) 4.45 a,b (3.33 – 5.56) 6.18 a,b (2.50 – 11.48) 32 a,b (20 – 47)
 Table 3   Inflammatory parameters in RA patients according to DAS28. 
 Data are expressed as median (interquartile range).  a p < 0.05 vs. healthy individuals,  b p < 0.05 vs. RA patients according to DAS28 
score  ≤ 2.6. 
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 Figure 2   Comparison of suPAR plasma levels (A), CRP plasma levels (B) and ESR (C) in healthy individuals and RA patients in remission 
grouped according to the number of tender and/or swollen joints. 
 Horizontal line: median, box: interquartile range, whisker: range.  a p < 0.05 vs. healthy individuals,  b p < 0.05 vs. RA patients with 0 – 1 tender 
and/or swollen joints,  c p < 0.05 vs. RA patients with 2 – 3 tender and/or swollen joints. 
Study group suPAR, ng/mL CRP, mg/L ESR, mm/h
Healthy individuals 2.80 (2.06 – 3.42) 2.70 (BLD – 4.15) 10 (7 – 14)
RA patients in remission (DAS28  ≤ 2.6) according to number of tender and/or swollen joints
   0 – 1 (45.3 % ) 3.04 (2.60 – 3.32) 2.50 (BLD – 5.73) 12 (8 – 18)
   2 – 3 (34.0 % ) 4.33 a,b (3.93 – 4.50) 2.70 (BLD – 5.43) 17 (12 – 18)
   4 (20.7 % ) 7.04 a,b,c (6.37 – 11.23) 2.60 (BLD – 10.40)   9 (4 – 37)
 Table 4   Inflammatory parameters in RA patients in remission. 
 Data are expressed as median (interquartile range).  a p < 0.05 vs. healthy individuals,  b p < 0.05 vs. RA patients with 0 – 1 tender 
and/or swollen joints,  c p < 0.05 vs. RA patients with 2 – 3 tender and/or swollen joints. 
evaluation than the presence or lack of clinical symptoms, 
especially in the follow-up of patients in remission with 
inflammatory activity. Based on previous studies, suPAR 
is a sensitive marker of inflammation. 
 In our study, suPAR levels as well as CRP 
and ESR values were elevated in a group of RA 
patients with various durations and activity of 
disease compared to healthy controls (Table 1). 
This is in agreement with earlier results of Slot 
et al. who also found higher plasma suPAR concentra-
tions in RA. Furthermore, in their study suPAR levels in 
RA were positively correlated to CRP and ESR values. 
They concluded that increased suPAR levels might 
reflect erosive activity in RA  [14] . It is of interest that we 
also found a correlation between ESR and DAS28 but 
not CRP values and suPAR levels investigating all RA 
patients (Figure 1A, B). A reason for this finding might 
be that in our study, ESR was used for the calculation of 
DAS28 scores, therefore, alterations of DAS28 are related 
to ESR values. Furthermore, the patients enrolled in our 
study were more heterogenous in terms of disease sever-
ity, including patients with milder RA. In contrast with 
the findings in RA, CRP values were correlated to suPAR 
levels in healthy individuals in our study (Figure 1C). 
 Next we investigated suPAR levels in different sub-
groups of RA patients. When RA patients were grouped 
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 Figure 3   ROC analysis of suPAR values in RA patients in remission. 
 Patients with four tender and/or swollen joints were regarded 
as patients under risk for clinical relapse. AUC: 0.996 (95 % CI 
0.984 – 1.007, p = 0.0001). 
according to anti-TNF and glucocorticoid therapy, or CRP 
and ESR values, no differences were detected between 
the corresponding subgroups. However, when we com-
pared RA subgroups according to DAS28 scores, a dif-
ference between RA patients in remission (DAS28  ≤ 2.6) 
and patients with different stages of active disease 
(DAS28  > 2.6) was noted (Table 2). 
 Recent studies demonstrated that suPAR has many 
advantages over CRP and ESR in the detection of low-
grade inflammation. In contrast with these markers, 
suPAR levels in healthy individuals are stable throughout 
the day, independently whether the subject is fasting or 
not  [15] . Furthermore, even repeated freeze-thaw proce-
dures of plasma samples do not affect suPAR concentra-
tions  [16] . Our results also suggest that suPAR is a more 
sensitive marker of inflammatory activity in RA patients in 
remission according to DAS28 scores. While CRP and ESR 
values were comparable with healthy individuals in this 
group of patients, suPAR values were elevated. However, 
suPAR levels in patients in remission were lower than in 
patients with DAS28  > 2.6. In contrast, CRP and ESR values 
were comparable in patients in remission and in healthy 
controls (Table 3). 
 Remission is defined as DAS28  ≤ 2.6. However, it has 
to be noted that if both ESR and visual analogue scale 
(VAS) values are low upon DAS28 assessment, the pres-
ence of a maximum of four tender and/or swollen joints 
still results in a DAS28 score corresponding to remission. 
Therefore, we investigated the presence of clinical symp-
toms in RA patients in remission, and further grouped 
them according to the number of tender and/or swollen 
joints. The number of affected joints was strongly cor-
related to elevated plasma suPAR levels, indicating that 
suPAR levels represent well the presence of ongoing 
inflammatory activity in RA patients in remission (Figure 
1D). Interestingly, higher levels of suPAR were associated 
with worse prognosis in several other diseases, includ-
ing infections  [5, 6] and tumors  [8, 10] . While CRP and 
ESR values were similar in all subgroups of RA patients 
in remission to the levels seen in healthy individuals, 
suPAR values were elevated indicating the inflamma-
tory activity in patients with 2 – 3 or four affected joints. 
Highest suPAR values were observed in patients with the 
highest number of affected joints. Of note, this subgroup 
(11 patients) gave almost 10 % of the whole RA group 
of our study and over 20 % of RA patients in remission, 
indicating that determination of the inflammatory activ-
ity in RA patients in remission based on plasma suPAR 
values might be regularly needed during follow-up. ROC 
analysis (Figure 3) revealed a suPAR cut-off value of 4.785 
ng/mL to identify patients under risk for clinical relapse 
(i.e., patients with four tender and/or swollen joints in 
contrast with patients with 0 – 3 tender and/or swollen 
joints). Moreover, recent data also indicated that patients 
in remission according to DAS28 scores could also have 
slowly progressive structural damage without relevant 
clinical symptoms and with normal CRP and ESR  [17] . 
In such cases only ultrasound investigation of the joints 
supports the presence of synovitis. However, the use of 
ultrasound has limited efficiency in detecting inflamma-
tion, since its availability is restricted, it is time-consum-
ing, and investigator-dependent. 
 In summary, suPAR is a sensitive and stable marker 
of inflammation in the monitoring of RA patients. Based 
on plasma suPAR levels, we have identified a subgroup 
of RA patients in remission according to DAS28 scores, 
who have clinical symptoms of inflammatory activity 
(tender and/or swollen joints) which correlate to ele-
vated plasma suPAR levels. Importantly, ESR and CRP 
values showed no alteration in these patients compared 
to healthy controls. Hence, suPAR might be particularly 
valuable in the recognition of inflammatory activity in 
patients who are in remission according to DAS28 scores 
but have clinical symptoms affecting joints. Monitoring 
of suPAR levels might be a very helpful tool for the fol-
low-up of patients in remission with mild clinical signs. 
Our finding might also have important therapeutic con-
sequences, since this group of patients identified by ele-
vated suPAR levels may receive earlier treatment of the 
inflammatory activity. 
 Acknowledgments :  This work was supported by the Hun-
garian Scientific Research Fund [OTKA; grant number 
101661]; the Medical Research Council [grant number 
ETT 05-180/2009]; and a research grant from Roche 
Hungary Ltd. 
Brought to you by | Semmelweis University of Medicine
Authenticated | 193.224.49.19
Download Date | 3/19/14 11:04 AM
332      Toldi et al.: suPAR levels in RA patients in remission
 Conflict of interest statement 
 Authors ’ conflict of interest disclosure: The authors stated that 
there are no conflicts of interest regarding the publication of this 
article. Research funding played no role in the study design; in the 
collection, analysis, and interpretation of data; in the writing of the 
report; or in the decision to submit the report for publication. 
 Research funding: None declared. 
 Employment or leadership: None declared. 
 Honorarium: None declared. 
Received April 4, 2012; accepted May 20, 2012; previously published 
online June 21, 2012
 References 
 1.  Dan ø K, Behrendt N, Br ü nner N, Ellis V, Ploug M, Pyke C. 
The urokinase receptor. Protein structure and role in 
plasminogen activation and cancer invasion. Fibrinolysis 
1994;8:189 – 203. 
 2.  Behrendt N, Stephens RW. The urokinase receptor. Fibrinolysis 
Proteol 1998;12:191 – 204. 
 3.  Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, H ø yer-
Hansen G, R ø nne E, et al. ELISA determination of soluble 
urokinase receptor in blood from healthy donors and cancer 
patients. Clin Chem 1997;43:1876 – 84. 
 4.  R ø nne E, Pappot H, Gr ø ndahl-Hansen J, H ø yer-Hansen G, Plesner 
T, Hansen NE, et al. The receptor for urokinase plasminogen 
activator is present in plasma from healthy donors and elevated 
in patients with paroxysmal nocturnal haemoglobinuria. Br J 
Haematol 1995;89:576 – 81. 
 5.  Ostergaard C, Benfield T, Lundgren JD, Eugen-Olsen J. Soluble 
urokinase receptor is elevated in cerebrospinal fluid from 
patients with purulent meningitis and is associated with fatal 
outcome. Scand J Infect Dis 2004;36:14 – 9. 
 6.  Ostrowski SR, Ullum H, Goka BQ, H ø yer-Hansen G, Obeng 
Adjei G, Pedersen BK, et al. Plasma concentrations of soluble 
urokinase-type plasminogen activator receptor are increased in 
patients with malaria and are associated with a poor clinical or a 
fatal outcome. J Infect Dis 2005;191:1331 – 41. 
 7.  Balabanov R, Lisak D, Beaumont T, Lisak RP, Dore-Duffy P. 
Expression of urokinase plasminogen activator receptor on 
monocytes from patients with relapsing-remitting multiple 
sclerosis: effect of glatiramer acetate (copolymer 1). Clin Diagn 
Lab Immunol 2001;8:1196 – 203. 
 8.  Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, 
et al. The level of urokinase-type plasminogen activator receptor 
is increased in serum of ovarian cancer patients. Cancer Res 
1998;58:1843 – 9. 
 9.  Toldi G, B í r ó E, Szalay B, Stenczer B, Molvarec A, Rig ó J Jr, 
et al. Soluble urokinase Plasminogen Activator Receptor (suPAR) 
 levels in healthy pregnancy and preeclampsia. Clin Chem Lab 
Med 2011;49:1873 – 6. 
 10.  Thun ø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal 
ball. Dis Markers 2009;27:157 – 72. 
 11.  Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, 
et al. Validation of the 28-joint Disease Activity Score (DAS28) 
and European League Against Rheumatism response criteria 
based on C-reactive protein against disease progression in 
patients with rheumatoid arthritis, and comparison with the 
DAS28 based on erythrocyte sedimentation rate. Ann Rheum 
Dis 2009;68:954 – 60. 
 12.  Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 
CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: 
an American College of Rheumatology/European League 
Against Rheumatism collaborative initiative. Arthritis Rheum 
2010;62:2569 – 81. 
 13.  [No authors listed] ICSH recommendations for measurement 
of erythrocyte sedimentation rate. International Council 
for Standardization in Haematology (Expert Panel on Blood 
Rheology) J Clin Pathol 1993;46:198 – 203. 
 14.  Slot O, Br ü nner N, Locht H, Oxholm P, Stephens RW. Soluble 
urokinase plasminogen activator receptor in plasma of patients 
with inflammatory rheumatic disorders: increased concentrations 
in rheumatoid arthritis. Ann Rheum Dis 1999;58:488 – 92. 
 15.  Sier CF, Sidenius N, Mariani A, Aletti G, Agape V, Ferrari A, 
et al. Presence of urokinase-type plasminogen activator 
receptor in urine of cancer patients and its possible clinical 
relevance. Lab Invest 1999;79:717 – 22. 
 16.  Riisbro R, Christensen IJ, H ø gdall C, Br ü nner N, H ø gdall E. Soluble 
urokinase plasminogen activator receptor measurements: 
influence of sample handling. Int J Biol Markers 2001;16:233 – 9. 
 17.  Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis 
progresses in remission according to the disease activity score 
in 28 joints and is driven by residual swollen joints. Arthritis 
Rheum 2011;63:3702 – 11. 
Brought to you by | Semmelweis University of Medicine
Authenticated | 193.224.49.19
Download Date | 3/19/14 11:04 AM
